ABBV

Key Stats for AbbVie StockCurrent Price: $285.

Analysts have raised AbbVie’s fair‑value estimate to $284.79, up from $278.61, and other targets now range from $260 to $325. The lift reflects confidence in its immunology, neuroscience and oncology pipeline, though some program risks remain.

AbbVie (NYSE: ABBV) today announced the U.S. Food and Drug Administration has approved a subcutaneous (SC) induction regimen for SKYRIZI® (risankizumab-rzaa) for adults with moderately to severely active Crohn's disease (CD)iv.

When a drugmaker's top product loses patent protection, the dividend usually takes the hit. Four pharma giants are each betting on newer drugs to fill the gap, but how close each one sits to the edge varies far more than the yields suggest.

AbbVie (NYSE:ABBV) today announced the U.S. Food and Drug Administration has approved a subcutaneous (SC) induction regimen for SKYRIZI® (risankizumab-rzaa) for adults with moderately to severely active Crohn's

Bristol Myers appears cheaper and offers a higher dividend than AbbVie, but both companies face pipeline execution challenges, declining legacy drugs and debt concerns.

Goldman Sachs upgraded AbbVie to a Neutral stance and lifted its price target from $258 to $294, signaling a more optimistic outlook.

AbbVie (ABBV) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.